Results 151 to 160 of about 33,429 (298)

Pinus pinea L. Periderm as a Sustainable Source of Phenolic Bioactives: Integrated Phytochemical, Antioxidant, and Elemental Investigation

Chemistry &Biodiversity, Volume 23, Issue 8, August 2026.
A hydroalcoholic extract from the renewable periderm of Pinus pinea is characterized through integrated phytochemical, biological and elemental analyses. The extract exhibits a phenolic‐rich composition, significant antioxidant activity and preliminary protection against oxidative stress in SH‐SY5Y cells, while elemental profiling indicates low levels ...
Vlad Sebastian Popescu, Fabjola Bilo, Eileen Mac Sweneey, Laura Borgese, Gregorio Peron, Giulia Abate, Andrea Mastinu   +6 more
wiley   +1 more source

Metabolism Profiles of Trimethoprim in Idiosyncratic Adverse Drug Reaction-Affected Tissues. [PDF]

Chem Res Toxicol
Tessman RT, Nolte W, Flores-Ascencio P, Goldman J.   +3 more
europepmc   +1 more source

Improved detection of opioid use in chronic pain patients through monitoring of opioid glucuronides in urine.

Journal of Analytical Toxicology, 2012
Jane A Dickerson, Thomas J. Laha, M. Pagano, Brendan R. O'donnell, A. Hoofnagle   +4 more
semanticscholar   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 387-393, August 2026.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source

Recent advances in the identification and quantification of xylazine and medetomidine in biological specimens. [PDF]

Bioanalysis
Crews BO.
europepmc   +1 more source

Effect of Late Second to Early Third Trimester of Pregnancy on the Activity of Renal Organic Anion Transporters (OAT1 and OAT3): A Biomarker Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 465-474, August 2026.
Pregnant individuals take drugs throughout pregnancy and many of these drugs (e.g., antivirals, antibiotics) are eliminated by renal organic anion transporters (OAT) 1 and OAT3. In vivo studies with OAT1/3 substrate drugs suggest that pregnancy increases renal OAT1/3 activities by 1.5‐ to 1.8‐fold.
Aarzoo Thakur, Jashvant D. Unadkat, Emily E. Fay, Nina Isoherranen, Mary F. Hebert   +4 more
wiley   +1 more source

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 492-500, August 2026.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel, Anina Zumtaugwald, Anna Bollinger, Chiara Jeiziner, Kurt E. Hersberger, Florine Wiss, Markus L. Lampert, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble   +9 more
wiley   +1 more source

Comprehensive Review on the Toxicity of Five Main AQ Constituents from Rhubarb: Mechanisms, Challenges and Future Perspectives. [PDF]

Drug Des Devel Ther
Yu L, Jiang Y, Li P, Wang J, Tang P, Zhao Y.   +5 more
europepmc   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Human exposure to green spaces and monoterpenes: discovery and use of α-pinene metabolites as biomarkers. [PDF]

Environ Int
Xie Z, Sutaria SR, Chen JY, Gao H, Conklin DJ, Keith RJ, Srivastava S, Lorkiewicz P, Bhatnagar A.   +8 more
europepmc   +1 more source